. "Appendix G: Costs and Benefits of Immunotherapies or Depot Medications for the Treatment of Drug Abuse." New Treatments for Addiction: Behavioral, Ethical, Legal, and Social Questions. Washington, DC: The National Academies Press, 2004.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
New Treatments for Addiction: Behavioral, Ethical, Legal, and Social Questions
Everingham, S.S., and Rydell, C.P. (1994). Modeling the demand for cocaine. Santa Monica, CA: RAND Corporation.
Fairbank, J.A., Dunteman, G.H., and Condelli, W.S. (1993). Do methadone patients substitute other drugs for heroin? Predicting substance use at 1-year follow-up. American Journal of Drug and Alcohol Abuse,19(4), 465-474.
Goldberg, J., and Fischoff, B. (2000). The long-term risks in the short-term benefits: Perceptions of potentially addictive activities. Health Psychology,19(3), 299-303.
Goldstein, A. (2001). Addiction: From biology to drug policy (Second Edition). New York: Oxford University Press.
Hser, Y., Hoffman, V., Grella, C.E., and Anglin, D. (2001). A 33-year follow-up of narcotics addicts. Archives of General Psychiatry,58(5), 503-508.
Hubbard, R.L., and French, M.T. (1991). New perspectives on the benefit-cost and cost-effectiveness of drug abuse treatment. In W.S. Cartwright and J.M. Kaple (Eds.), Economic costs, cost-effectiveness, financing, and community-based drug treatment (pp. 94-113). Rockville, MD: National Institute on Drug Abuse.
Institute of Medicine. (1990). Treating drug problems, volume 1. Committee for the Substance Abuse Coverage Study, D.R. Gerstein and H.J. Harwood (Eds.). Washington, DC: National Academy Press.
Johnson, B.D., Rosenblum, A., and Kleber, H. (2003). A new opportunity to expand treatment for heroin users in New York City: Public policy challenges for bringing buprenorphine into drug treatment programs and general medical practice. White paper for New York City Department of Health and Mental Hygiene. Available: http://www.nyc.gov/html/doh/pdf/public/dmh/whitepaper.pdf [August 21, 2003].
Kleiman, M.A.R. (1999). Economic cost measurements, damage minimization and drug abuse control policy. Addiction,94(5), 638-641.
MacCoun, R.J. (1993). Drugs and the law: A psychological analysis of drug prohibition. Psychological Bulletin,113(3), 497-512.
MacCoun, R.J., Reuter, P., and Schelling, T. (1996). Assessing alternative drug control regimes. Journal of Policy Analysis and Management, 15(3), 330-352.
McKay, J.R., Rutherford, M.J., Cacciola, J.S., Kabasakalian-McKay, R., and Alterman, A.I. (1996). Gender differences in the relapse experiences of cocaine patients. Journal of Nervous and Mental Disease,184(10), 616-622.
Moore, M.H. (1990). Supply reduction and drug law enforcement. In M. Tonry and J.Q. Wilson (Eds.), Drugs and crime (pp. 109-158). Chicago: University of Chicago Press.
National Research Council. (2001). Informing America’s policy on illegal drugs: What we don’t know keeps hurting us. Committee on Data and Research for Policy on Illegal Drugs. C.F. Mansiki, J.V. Pepper, and C.V. Petrie (Eds.). Committee on Law and Justice and Committee on National Statistics. Commission on Behavioral and Social Sciences and Education. Washington, DC: National Academy Press.